DSIP vs Semax
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
DSIP
DSIP (Delta Sleep Inducing Peptide) is a nonapeptide (9 amino acids) first isolated from rabbit thalamus in 1974, initially believed to directly induce slow-wave (delta) sleep. Research has since broadened its profile considerably: it modulates the HPA axis (reducing stress-driven cortisol), influences GH and LH release, demonstrates antioxidant properties, and may have cardioprotective effects. Despite decades of research, its precise receptor system remains incompletely characterized.
Full profileSemax
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) — specifically the 4–7 fragment modified with a C-terminal Pro-Gly-Pro extension for stability. Developed in Russia in the 1980s and used clinically there for stroke recovery, cognitive enhancement, and neuroprotection, it is one of the most researched nootropic peptides with a decades-long safety record in Eastern European clinical practice. Its primary mechanism involves potent upregulation of BDNF (Brain-Derived Neurotrophic Factor).
Full profile| DSIP | Semax | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | Delta Sleep Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu | ACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 100mcg–500mcg mcg, Once daily (evening) or every other day | 200mcg–900mcg mcg, Once or twice daily (intranasal most common) |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies) | Intranasal (preferred — high CNS bioavailability), Subcutaneous injection |
| Key side effects | Generally well-tolerated, Daytime drowsiness if dosed in morning, Mild headache, Altered dream quality (common) | Mild anxiety or restlessness at high doses, Nasal irritation (intranasal route), Increased energy / difficulty sleeping if dosed too late in the day, Mild appetite suppression |
| Cited sources | 3 references | 3 references |
Key differences
- Evidence level differs: DSIP is research-stage, while Semax is investigational (in trials).
- Administration: DSIP — Subcutaneous injection, Intranasal, Intravenous (clinical studies); Semax — Intranasal (preferred — high CNS bioavailability), Subcutaneous injection.
- Frequency: DSIP is typically Once daily (evening) or every other day; Semax is Once or twice daily (intranasal most common).
How each works
DSIP
DSIP does not directly trigger sleep in the simple sense originally proposed — more recent research indicates it modulates the neuroendocrine environment that facilitates sleep. Key findings: it reduces ACTH-driven cortisol elevation under stress, increases GH secretion in some models, and attenuates withdrawal severity in opioid and alcohol dependence (mechanisms unclear). DSIP demonstrates antioxidant effects and has cardioprotective properties in ischemic preconditioning models in animals. Its unique resistance to most peptidases (attributed to its unusual conformation) gives it a relatively long half-life for a nonapeptide.
Semax
Semax increases BDNF expression in the hippocampus and frontal cortex by 1.3–1.6x at research doses in rodent models. It also upregulates NGF (nerve growth factor) and modulates serotonin, dopamine, and NMDA receptor systems. Russian clinical data (not yet replicated in Western trials) suggests efficacy in ischemic stroke recovery, ADHD, glaucoma, and cognitive decline. The Pro-Gly-Pro C-terminal extension dramatically improves resistance to enzymatic degradation compared to native ACTH(4-7).
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.